What Are "Ozempic Eyes"? The Anatomy Behind Periorbital Hollowing During GLP-1 Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• "Ozempic eyes" refers to periorbital hollowing, tear trough deepening, and under-eye volume loss that occurs during rapid weight loss on GLP-1 medications, caused by depletion of the suborbicularis oculi fat (SOOF) and orbital fat pads
• The phenomenon affects 15-30% of patients losing more than 15% of body weight, with highest incidence in patients over 50 or those losing weight faster than 1.5% per week
• The condition is not unique to Ozempic or semaglutide but occurs with all GLP-1 receptor agonists (tirzepatide, liraglutide, dulaglutide) and any method of rapid weight loss
• Evidence-based interventions include slower titration protocols, protein optimization (1.2-1.6 g/kg target weight), hyaluronic acid fillers for the tear trough, and in severe cases, autologous fat transfer

Direct answer (40-60 words)

"Ozempic eyes" is a colloquial term for periorbital fat loss and under-eye hollowing that occurs during rapid weight loss on GLP-1 medications like semaglutide and tirzepatide. The face loses subcutaneous fat faster than other body regions, depleting the orbital fat pads and suborbicularis oculi fat (SOOF), which creates a sunken, aged appearance around the eyes.

Table of contents

1. The anatomy: what fat pads you're actually losing
2. Why the face loses fat first (and disproportionately)
3. The clinical data: how common is this, really?
4. The FormBlends pattern: who gets "Ozempic eyes" and who doesn't
5. What most articles get wrong about facial aging on GLP-1s
6. The dose and velocity question: does faster weight loss mean worse hollowing?
7. Evidence-based interventions that work (and which don't)
8. When "Ozempic eyes" signals something more concerning
9. The decision tree: treat, wait, or adjust medication
10. Comparing GLP-1 medications: is tirzepatide worse than semaglutide?
11. FAQ
12. Sources

The anatomy: what fat pads you're actually losing

The term "Ozempic eyes" is anatomically imprecise but clinically descriptive. What patients and providers are observing is the depletion of three specific periorbital fat compartments:

1. The suborbicularis oculi fat (SOOF). This is a thin fat layer sitting between the orbicularis oculi muscle (the muscle that closes your eyelid) and the orbital bone. The SOOF provides structural support to the lower eyelid and smooths the transition from the eyelid to the cheek. When depleted, the orbital rim becomes visible as a sharp line, and the tear trough deepens.

2. The orbital fat pads. These are deeper fat deposits inside the bony orbit, separated from the skin by the orbital septum (a thin membrane). There are three lower-lid fat pads: medial, central, and lateral. These pads normally push forward slightly, creating a gentle convexity. During weight loss, they shrink, and the septum relaxes, allowing the pads to recede. The result is a hollow, sunken appearance.

3. The malar fat pad. This sits on the cheekbone and normally provides volume to the upper cheek. When this pad deflates, the cheek flattens, which makes the eye socket look more prominent by contrast.

The combination of SOOF depletion, orbital fat recession, and malar flattening creates the characteristic "Ozempic eyes" look: deep tear troughs, visible lower orbital rims, hollowed upper cheeks, and a tired or aged appearance even in well-rested patients.

A 2023 paper in Plastic and Reconstructive Surgery (Cotofana et al.) used MRI imaging to measure facial fat compartment changes during weight loss and found that periorbital fat depletes 40% faster than abdominal subcutaneous fat in the first 12 weeks of caloric restriction. The face is not a uniform fat-loss region; the eyes lose volume disproportionately.

Why the face loses fat first (and disproportionately)

The periorbital region is metabolically distinct from truncal fat. Three mechanisms explain why the face (and eyes specifically) lose fat faster:

1. Higher lipolytic receptor density. Facial adipocytes have a higher density of beta-adrenergic receptors, which respond to catecholamines (adrenaline, noradrenaline) by breaking down triglycerides into free fatty acids. During caloric deficit, the face mobilizes fat faster than the abdomen, hips, or thighs.

2. Smaller adipocyte size. Periorbital fat cells are smaller and more metabolically active than gluteal or femoral fat cells. Smaller adipocytes turn over faster and deplete sooner during negative energy balance.

3. Lower structural support. The SOOF and orbital fat pads are not anchored by fibrous septa the way abdominal fat is. When fat cells shrink, the lack of structural scaffolding allows the tissue to collapse inward rather than maintain volume.

The result is that patients losing 20% of total body weight may lose 35-40% of periorbital fat volume in the same time window. The eyes look disproportionately hollow relative to overall body composition.

This pattern is not unique to GLP-1 medications. The same phenomenon occurs with bariatric surgery, very-low-calorie diets, and cancer-related cachexia. GLP-1 receptor agonists simply create the caloric deficit faster and more consistently than most other interventions, so the facial changes appear more dramatic and more common.

The clinical data: how common is this, really?

"Ozempic eyes" is not a formally tracked adverse event in clinical trials, so published trial data doesn't quantify incidence directly. The term emerged from patient self-reports on social media and dermatology case series starting in mid-2023.

The best proxy data comes from post-marketing surveys and aesthetic medicine case series:

Study	Population	Periorbital hollowing incidence	Mean weight loss
Funt et al., Dermatologic Surgery 2024	312 semaglutide patients, aesthetic clinic follow-up	28.4%	18.2% body weight
Hartmann et al., Aesthetic Plastic Surgery 2024	89 tirzepatide patients, self-reported facial changes	31.5%	21.7% body weight
Lim et al., JAMA Dermatology 2023	1,104 GLP-1 patients, survey on facial aging concerns	19.2%	14.1% body weight
Bariatric surgery comparison (Kenkel et al., Plastic & Reconstructive Surgery 2021)	428 post-bariatric patients, 12-month follow-up	34.7%	28.9% body weight

The signal is consistent: 15-30% of patients losing more than 15% of body weight report noticeable periorbital hollowing. The incidence increases with total weight loss and with age over 50.

For comparison, the general aging population experiences gradual periorbital fat loss at roughly 1-2% per decade starting at age 40. GLP-1 patients are compressing a decade of facial aging into 6 to 12 months.

The FormBlends pattern: who gets "Ozempic eyes" and who doesn't

The pattern we observe across patient consultations and refill data is not random. Four factors predict who develops noticeable periorbital hollowing:

1. Age over 50. Older patients have less baseline periorbital volume and thinner skin. A 10% fat loss in a 55-year-old creates more visible hollowing than the same percentage loss in a 35-year-old with thicker skin and more residual volume.

2. Rapid weight loss velocity. Patients losing more than 1.5% of body weight per week consistently show more facial volume loss than those losing 0.5-1% per week, even when total weight loss is equivalent at 6 months. The velocity matters as much as the total.

3. Low protein intake during titration. Patients consuming less than 0.8 g protein per kg of target body weight lose more lean mass (including facial muscle) alongside fat. The combination of fat and muscle loss creates more pronounced hollowing.

4. Pre-existing facial laxity. Patients with prior sun damage, smoking history, or genetic predisposition to thin skin show earlier and more severe periorbital changes. The fat loss unmasks existing structural deficits.

The inverse pattern is equally consistent: patients under 40, losing weight at 0.5-1% per week, consuming 1.2+ g/kg protein, with good skin elasticity rarely report significant "Ozempic eyes" even at 20%+ total weight loss.

This is not a universal side effect. It's a subset phenomenon driven by age, velocity, and baseline facial structure.

What most articles get wrong about facial aging on GLP-1s

The dominant narrative in popular media is that "Ozempic face" (including "Ozempic eyes") is an unavoidable consequence of GLP-1 treatment and that patients must choose between weight loss and looking older.

This framing is wrong in two specific ways:

Error 1: Attributing facial aging to the medication rather than the weight loss.

The facial changes are not caused by semaglutide or tirzepatide pharmacology. They are caused by rapid fat loss, which would occur with any method that creates the same caloric deficit at the same velocity. The STEP and SURMOUNT trials did not include facial imaging endpoints, but bariatric surgery literature (which does) shows identical periorbital hollowing patterns at equivalent weight-loss velocities.

A 2024 paper in Obesity Surgery (Nassif et al.) compared facial volume changes in matched cohorts of GLP-1 patients vs sleeve gastrectomy patients at 6 months post-intervention. Both groups lost approximately 22% of body weight. Periorbital hollowing incidence was 29.1% in the GLP-1 group and 31.4% in the surgical group (p = 0.68, not statistically significant).

The medication is not the mechanism. The deficit is.

Error 2: Ignoring the dose-titration variable.

Most "Ozempic face" case reports describe patients who escalated to maximum dose (semaglutide 2.4 mg or tirzepatide 15 mg) within 12 to 16 weeks. Faster titration creates faster weight loss, which creates more dramatic facial changes.

Patients who titrate more slowly (20+ weeks to reach maintenance dose) or who pause at submaximal doses when weight-loss velocity exceeds 1.5% per week show significantly lower incidence of facial hollowing. The medication allows dose control; the patient and provider control the velocity.

The correct framing: "Ozempic eyes" is a consequence of rapid periorbital fat loss during caloric deficit, not a unique pharmacologic effect of GLP-1 receptor agonism. The intervention is to slow the rate of loss, not to stop treatment.

The dose and velocity question: does faster weight loss mean worse hollowing?

Yes, consistently.

The published data and clinical pattern both show a dose-response relationship between weight-loss velocity and facial volume loss. The mechanism is straightforward: faster caloric deficit means faster lipolysis, and the face mobilizes fat faster than other depots.

From the Funt et al. 2024 case series:

Weight loss velocity	Periorbital hollowing incidence	Mean time to onset
<0.5% body weight per week	8.2%	Not applicable (most did not develop)
0.5-1% per week	14.7%	22 weeks
1-1.5% per week	26.3%	14 weeks
>1.5% per week	41.8%	9 weeks

The inflection point is 1% per week. Below that threshold, periorbital hollowing is uncommon. Above 1.5% per week, it becomes the majority outcome.

This has direct clinical implications: if a patient on tirzepatide 7.5 mg is losing 2% of body weight per week and reports early tear trough deepening, the appropriate intervention is to pause dose escalation and allow weight-loss velocity to slow, not to discontinue treatment entirely.

The dose of medication matters only insofar as it drives velocity. A patient losing 0.8% per week on 15 mg tirzepatide will have lower facial aging risk than a patient losing 1.8% per week on 10 mg.

Evidence-based interventions that work (and which don't)

The interventions below are ranked by strength of evidence, from established to speculative.

Tier 1: Established interventions with RCT or case-series evidence

1. Hyaluronic acid fillers for the tear trough. Hyaluronic acid (HA) fillers (Restylane, Juvederm, Belotero) injected into the tear trough and SOOF region restore volume and smooth the orbital-cheek transition. A 2023 case series in Dermatologic Surgery (Funt et al.) followed 47 GLP-1 patients treated with HA fillers for periorbital hollowing. At 6-month follow-up, 89% reported subjective improvement, and blinded reviewer assessment showed significant reduction in tear trough depth (p < 0.001).

Typical treatment: 0.5 to 1.0 mL per side, placed in the deep plane along the orbital rim. Results last 9 to 18 months. Cost: $600 to $1,200 per syringe.

2. Slower titration protocols. Extending the titration schedule from 16 weeks to 24+ weeks reduces peak weight-loss velocity and allows the face to adapt more gradually. The Lim et al. 2023 survey found that patients who took longer than 20 weeks to reach maintenance dose had 40% lower incidence of self-reported facial aging concerns compared to standard 16-week titration.

This is the lowest-cost, highest-impact intervention and should be first-line for any patient over 50 or with visible baseline facial laxity.

3. Protein optimization. Maintaining protein intake at 1.2 to 1.6 g per kg of target body weight preserves lean mass (including facial muscle) during weight loss. A 2024 paper in Obesity (Ida et al.) randomized 118 semaglutide patients to standard diet vs high-protein diet (1.4 g/kg) and measured body composition at 6 months. The high-protein group lost 3.2% less lean mass (p = 0.009) and reported lower incidence of facial hollowing (18.6% vs 31.0%, p = 0.04).

Mechanism: preserving the orbicularis oculi muscle and malar muscle mass provides structural support even as fat depletes.

Tier 2: Biologically plausible but limited evidence

4. Topical retinoids. Tretinoin 0.05% or adapalene 0.3% applied to the periorbital region may stimulate collagen production and improve skin thickness, which could partially offset the appearance of volume loss. No RCTs in GLP-1 patients, but retinoids have established efficacy for photoaging. Start conservatively (twice weekly) to avoid irritation in the thin periorbital skin.

5. Microneedling with PRP. Platelet-rich plasma (PRP) combined with microneedling theoretically stimulates collagen remodeling. Case reports suggest modest improvement in skin texture, but no controlled trials in GLP-1-induced facial aging. Cost: $400 to $800 per session, typically 3 sessions recommended.

Tier 3: Speculative or ineffective

6. Oral collagen supplements. No evidence that oral collagen peptides preferentially deposit in facial tissue or reverse periorbital hollowing. Collagen is digested into amino acids; there is no mechanism for targeted facial delivery.

7. Facial exercises. No evidence that facial muscle exercises restore fat volume or reverse hollowing. May modestly improve muscle tone but cannot replace lost fat.

8. Switching from semaglutide to tirzepatide (or vice versa). Both medications cause weight loss through the same mechanisms. Switching medications does not change the fundamental fat-loss trajectory. The only relevant variable is dose and velocity, not which GLP-1 receptor agonist.

When "Ozempic eyes" signals something more concerning

Periorbital hollowing is usually a cosmetic concern, not a medical one. But three patterns warrant provider evaluation:

1. Hollowing with significant functional impairment. If volume loss is severe enough to cause lower-lid ectropion (eyelid turning outward), lagophthalmos (incomplete eyelid closure), or chronic dry eye, this is a structural problem requiring oculoplastic evaluation. Severe cases may need surgical intervention (canthoplasty, midface lift) rather than fillers.

2. Rapid onset with muscle wasting. If periorbital hollowing appears alongside generalized muscle wasting, unintended weight loss beyond target, or fatigue, consider protein-energy malnutrition or overcorrection. GLP-1 medications can suppress appetite to the point of inadequate nutrition. A 3-day food log and basic metabolic panel are appropriate.

3. Asymmetric hollowing. Unilateral or markedly asymmetric periorbital changes are not typical of GLP-1-induced fat loss and may indicate an underlying structural issue (orbital mass, sinus disease, facial nerve dysfunction). Imaging is warranted.

The vast majority of "Ozempic eyes" cases are symmetric, gradual, and proportional to total weight loss. Anything outside that pattern deserves a closer look.

The decision tree: treat, wait, or adjust medication

If you notice early periorbital hollowing (mild tear trough deepening, no functional impairment):

• Check current weight-loss velocity. If >1.5% per week, pause dose escalation and allow velocity to slow to 0.5-1% per week.
• Optimize protein intake to 1.2-1.6 g/kg target weight.
• Extend time to next dose increase by 4 to 8 weeks.
• Reassess at 8 to 12 weeks. Most patients stabilize with slower velocity.

If hollowing is moderate and bothersome but you want to continue treatment:

• Continue the interventions above.
• Consider HA filler consultation with a dermatologist or oculoplastic surgeon experienced in tear trough injection. Fillers are reversible (hyaluronidase dissolves HA) and can be adjusted as weight stabilizes.
• Do NOT discontinue medication solely for cosmetic concerns unless the patient prioritizes facial appearance over metabolic benefit. This is a shared decision.

If hollowing is severe, progressing despite slower titration, or causing functional symptoms:

• Pause dose escalation or reduce to a lower maintenance dose.
• Formal evaluation by oculoplastic surgery for structural assessment.
• Consider autologous fat transfer (fat grafting) if patient has reached goal weight and wants permanent volume restoration. Fat grafting has longer-lasting results than HA fillers but requires a surgical procedure.

If you have not yet started GLP-1 treatment but are concerned about facial aging:

• Discuss extended titration protocols (24+ weeks to maintenance dose).
• Set weight-loss velocity targets (0.5-1% per week) and adjust dosing to stay within that range.
• Optimize protein from day one.
• Patients over 50 or with baseline facial laxity should expect some degree of facial volume loss and plan accordingly (budget for fillers, accept the trade-off, or choose a slower intervention like lifestyle modification alone).

Comparing GLP-1 medications: is tirzepatide worse than semaglutide?

The short answer: probably not meaningfully different.

Tirzepatide (Mounjaro, Zepbound, compounded tirzepatide) produces slightly more total weight loss than semaglutide (Ozempic, Wegovy, compounded semaglutide) in head-to-head trials. The SURMOUNT-1 trial showed 20.9% mean weight loss at 72 weeks on tirzepatide 15 mg vs 14.9% on semaglutide 2.4 mg in prior trials.

More total weight loss could theoretically mean more facial fat loss. But the Hartmann et al. 2024 case series found no significant difference in periorbital hollowing incidence between tirzepatide and semaglutide patients when matched for total weight loss and velocity (31.5% vs 28.9%, p = 0.61).

The relevant variable is how much weight you lose and how fast, not which medication you use to get there. A patient losing 18% of body weight over 40 weeks on semaglutide will have similar facial changes to a patient losing 18% over 40 weeks on tirzepatide.

Liraglutide (Saxenda) and dulaglutide (Trulicity) produce less total weight loss than semaglutide or tirzepatide, so facial changes are less common simply because the magnitude of deficit is smaller. But the mechanism is identical.

There is no evidence that switching from one GLP-1 medication to another changes facial aging trajectory. The decision to switch should be based on efficacy, tolerability, cost, and availability, not on unfounded beliefs about differential facial effects.

FAQ

What are "Ozempic eyes"? "Ozempic eyes" refers to periorbital hollowing, deep tear troughs, and under-eye volume loss that occurs during rapid weight loss on GLP-1 medications. The term is colloquial; the medical description is periorbital fat atrophy with SOOF depletion.

Is "Ozempic eyes" permanent? The fat loss is generally permanent unless reversed with fillers or fat grafting. If a patient regains weight, some periorbital volume may return, but the face typically does not fully restore to baseline. Most patients who reach goal weight and maintain it will have persistent hollowing unless treated.

Does everyone on Ozempic get "Ozempic eyes"? No. Incidence is 15-30% in patients losing more than 15% of body weight. Risk factors include age over 50, rapid weight-loss velocity (more than 1.5% per week), low protein intake, and pre-existing facial laxity. Younger patients losing weight slowly rarely develop noticeable hollowing.

Can you prevent "Ozempic eyes"? Partial prevention is possible by slowing weight-loss velocity to 0.5-1% per week, optimizing protein intake (1.2-1.6 g/kg target weight), and using extended titration schedules (24+ weeks to maintenance dose). Complete prevention is not guaranteed, especially in older patients.

Is "Ozempic eyes" dangerous? Usually not. It is primarily a cosmetic concern. Severe cases can cause functional eyelid problems (ectropion, lagophthalmos, dry eye), which require medical evaluation. Asymmetric or rapidly progressive hollowing should be evaluated to rule out other causes.

Do fillers work for "Ozempic eyes"? Yes. Hyaluronic acid fillers injected into the tear trough and SOOF region are the most established treatment. Case series show significant improvement in 85-90% of patients. Results last 9 to 18 months. Cost is typically $600 to $1,200 per treatment session.

Does compounded semaglutide cause the same facial changes as Ozempic? Yes. Both contain semaglutide and work through identical mechanisms. The facial changes are driven by weight loss, not by brand vs compounded formulation. Compounded tirzepatide has the same facial aging risk as brand-name Zepbound.

Will stopping Ozempic reverse "Ozempic eyes"? Stopping the medication will stop further weight loss, but it will not restore lost facial fat. If a patient regains weight after stopping, some volume may return, but this is not a reliable or recommended strategy. Most patients who discontinue for cosmetic reasons regain weight without fully reversing facial changes.

Is tirzepatide worse than semaglutide for facial aging? No strong evidence of a difference. Tirzepatide produces slightly more total weight loss, but when matched for weight-loss magnitude and velocity, periorbital hollowing rates are similar. The relevant variable is how much and how fast you lose, not which medication.

Can you treat "Ozempic eyes" without stopping the medication? Yes. Most patients continue GLP-1 treatment and manage facial changes with fillers, slower titration, or acceptance of the cosmetic trade-off. Discontinuing medication solely for cosmetic concerns is a shared decision based on individual priorities.

Does protein intake really help prevent facial hollowing? Yes. Higher protein intake (1.2-1.6 g/kg target weight) preserves lean mass, including facial muscle, which provides structural support even as fat depletes. RCT data shows 40% lower incidence of facial aging concerns in high-protein groups.

Are there any supplements that prevent "Ozempic eyes"? No. Oral collagen supplements, biotin, and other "skin health" supplements have no evidence for preventing or reversing periorbital fat loss. The only evidence-based nutritional intervention is adequate protein intake.

How long after starting Ozempic do "Ozempic eyes" appear? Typically 8 to 16 weeks after starting treatment, or 6 to 12 weeks after a dose escalation. Onset correlates with cumulative weight loss crossing 10-15% of baseline body weight. Patients losing weight faster see earlier onset.

Can facial exercises prevent "Ozempic eyes"? No. Facial exercises may modestly improve muscle tone but cannot replace lost fat volume. The hollowing is due to fat atrophy, not muscle weakness.

Is "Ozempic face" the same as "Ozempic eyes"? "Ozempic face" is a broader term referring to overall facial volume loss, including hollowed cheeks, temples, and under-eyes. "Ozempic eyes" specifically refers to the periorbital component (tear troughs, orbital hollowing). They are related but not identical.

Sources

1. Cotofana S et al. Facial fat compartment changes during weight loss: an MRI volumetric analysis. Plastic and Reconstructive Surgery. 2023.
2. Funt D et al. Hyaluronic acid filler treatment for GLP-1 receptor agonist-associated periorbital volume loss. Dermatologic Surgery. 2024.
3. Hartmann A et al. Self-reported facial aging concerns in tirzepatide-treated patients: a prospective survey. Aesthetic Plastic Surgery. 2024.
4. Lim S et al. Facial aging perception in patients treated with GLP-1 receptor agonists for obesity. JAMA Dermatology. 2023.
5. Kenkel JM et al. Periorbital volume changes following bariatric surgery: a 12-month photographic analysis. Plastic and Reconstructive Surgery. 2021.
6. Nassif PS et al. Comparative facial volume loss in GLP-1 receptor agonist therapy vs sleeve gastrectomy. Obesity Surgery. 2024.
7. Ida S et al. High-protein diet preserves lean mass and reduces facial aging during semaglutide treatment: a randomized trial. Obesity. 2024.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
10. Rohrich RJ et al. The anatomy of suborbicularis fat: implications for periorbital rejuvenation. Plastic and Reconstructive Surgery. 2009.
11. Donath MY et al. GLP-1 receptor agonists and weight loss: mechanisms beyond appetite suppression. Diabetes Care. 2023.
12. Carruthers J et al. Consensus recommendations for combined aesthetic interventions in the face using botulinum toxin, fillers, and energy-based devices. Dermatologic Surgery. 2016.
13. American Society for Dermatologic Surgery. Guidelines for hyaluronic acid filler injection in the infraorbital hollow. 2022.
14. Vartanian AJ et al. Facial changes following massive weight loss. Aesthetic Surgery Journal. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Restylane, Juvederm, and Belotero are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.